Prescient Therapeutics Limited (PTX.AX)

0,0450 -0,0020 (-4,26%) Börsenschluss: 04:10PM AEST

Prescient Therapeutics Limited

100 Albert Road
Level 4
Melbourne, VIC 3205
Australia
61 3 9692 7222
https://ptxtherapeutics.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Steven Lee Yatomi-Clarke	MD, CEO & Director	595,35k	N/A	N/A
Upaly Bahadure	Director of Clinical Affairs & Operations	N/A	N/A	N/A
Dr. Terrence G. Chew	Chief Medical Officer	155,99k	N/A	1947
Ms. Rebecca Lim	Senior Vice President of Scientific Affairs	N/A	N/A	N/A
Ms. Melanie Jaye Leydin B.Bus, C.A.	Company Secretary	158,4k	N/A	1973

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in AUD.

Beschreibung

Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of various cancers in Australia. Its lead drug candidate is PTX-200, which is in Phase 2a clinical trial for HER2-negative breast cancer, Phase IB/2 clinical trial in relapsed and refractory AML, and Phase 1b in recurrent or persistent platinum-resistant ovarian cancer; and PTX-100, a RhoA inhibitor, for hematological and solid malignancies that focuses on cancers with Ras and RhoA mutations. It has a strategic collaboration with The University of Texas MD Anderson Cancer Center to develop blood cancer binder for OmniCAR. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. The company was incorporated in 1986 and is based in Melbourne, Australia.

Corporate Governance

Prescient Therapeutics Limiteds ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.